[go: up one dir, main page]

WO2011162523A2 - Composition pour prévenir ou traiter l'ostéoporose, contenant du ssangwhatang ou un produit fermenté par lactobacillus de celui-ci - Google Patents

Composition pour prévenir ou traiter l'ostéoporose, contenant du ssangwhatang ou un produit fermenté par lactobacillus de celui-ci Download PDF

Info

Publication number
WO2011162523A2
WO2011162523A2 PCT/KR2011/004495 KR2011004495W WO2011162523A2 WO 2011162523 A2 WO2011162523 A2 WO 2011162523A2 KR 2011004495 W KR2011004495 W KR 2011004495W WO 2011162523 A2 WO2011162523 A2 WO 2011162523A2
Authority
WO
WIPO (PCT)
Prior art keywords
ssanghwatang
lactobacillus
weight
lactic acid
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/004495
Other languages
English (en)
Korean (ko)
Other versions
WO2011162523A3 (fr
Inventor
마진열
심기석
이지혜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Priority to CN201180038177.5A priority Critical patent/CN103037882B/zh
Publication of WO2011162523A2 publication Critical patent/WO2011162523A2/fr
Publication of WO2011162523A3 publication Critical patent/WO2011162523A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • Organic solvents that can be used include, but are not limited to, C 1 to C 4 lower alcohols, acetone, or aqueous solutions thereof.
  • the "ssanghwatang" is used to include not only the extraction of the medicinal mixture using water, but also all extracted using an organic solvent other than water.
  • the extracted femur was fixed in 10% formalin and then demineralized with formic acid, and then dehydrated with paraffin from 70% alcohol to 100% alcohol and acetone.
  • Paraffin-embedded bone tissue was cut to a thickness of 3 ⁇ m and stained with hematoxylin and eosin (hematoxyline & eosin, H & E). After observing the tissue with an optical microscope (Nikon eclipse 80i, Nikon, Japan), the degree of bone loss of trabeculae was analyzed.
  • Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh using a grinder.
  • Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.
  • Ssanghwatang or Ssanghwatang fermented products were decompressed and concentrated in a vacuum concentrator, dried by spraying and drying with a hot air dryer, and then pulverized with a particle size of 60 mesh to obtain a dry powder.
  • the grains, seeds and the dry powder of Ssanghwatang or Ssanghwatang fermentation prepared above were blended in the following ratio.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour prévenir ou traiter l'ostéoporose, et plus spécifiquement, une composition pharmaceutique et un supplément alimentaire pour prévenir ou traiter l'ostéoporose, contenant du Ssangwhatang, ou un produit fermenté par lactobacillus de celui-ci préparé par inoculation par un lactobacillus du Ssangwhatang et fermentation de celui-ci, en tant que substance active. La composition contenant du Ssangwhatang ou un produit fermenté par lactobacillus de celui-ci de la présente invention peut supprimer de façon remarquable la différenciation des ostéoclastes et l'expression de gènes apparentés et augmente la densité osseuse dans un essai in vivo, et peut être utilisée pour prévenir et/ou traiter l'ostéoporose.
PCT/KR2011/004495 2010-06-23 2011-06-20 Composition pour prévenir ou traiter l'ostéoporose, contenant du ssangwhatang ou un produit fermenté par lactobacillus de celui-ci Ceased WO2011162523A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201180038177.5A CN103037882B (zh) 2010-06-23 2011-06-20 包含双和汤或其乳酸菌发酵物的用于预防或治疗骨质疏松症的组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100059589A KR101252639B1 (ko) 2010-06-23 2010-06-23 쌍화탕 또는 이의 유산균 발효물을 포함하는 골다공증 예방 또는 치료용 조성물
KR10-2010-0059589 2010-06-23

Publications (2)

Publication Number Publication Date
WO2011162523A2 true WO2011162523A2 (fr) 2011-12-29
WO2011162523A3 WO2011162523A3 (fr) 2012-04-12

Family

ID=45371935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004495 Ceased WO2011162523A2 (fr) 2010-06-23 2011-06-20 Composition pour prévenir ou traiter l'ostéoporose, contenant du ssangwhatang ou un produit fermenté par lactobacillus de celui-ci

Country Status (3)

Country Link
KR (1) KR101252639B1 (fr)
CN (1) CN103037882B (fr)
WO (1) WO2011162523A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104367617A (zh) * 2014-11-06 2015-02-25 成都果睿医药科技有限公司 治疗骨质疏松的药物组合物
CN104435082A (zh) * 2014-11-06 2015-03-25 成都果睿医药科技有限公司 治疗骨质疏松的药物组合物
CN111718873A (zh) * 2020-06-19 2020-09-29 江南大学 一株具有缓解骨质疏松功效的发酵乳杆菌及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104398720A (zh) * 2014-11-06 2015-03-11 成都果睿医药科技有限公司 治疗骨质疏松的药物组合物
CN106501434B (zh) * 2016-12-30 2018-06-05 天津同仁堂集团股份有限公司 一种双和汤标准汤的hplc指纹图谱测定方法
TWI604052B (zh) 2017-02-20 2017-11-01 景岳生物科技股份有限公司 促進骨質再生的植物乳桿菌菌株ｇｍｎｌ－６６２及其組合物
CN108624520B (zh) * 2017-03-16 2022-01-25 景岳生物科技股份有限公司 促进骨质再生的植物乳杆菌菌株gmnl-662及其组合物
CA3103326A1 (fr) * 2018-06-18 2019-12-26 Probi Ab Compositions probiotiques et leurs utilisations
KR102164906B1 (ko) * 2018-09-12 2020-10-14 (주)성운파마코피아 락토바실러스 살리바리우스 swpm101 및 락토바실러스 가세리 swpm102를 포함하는 골질환의 예방, 개선 또는 치료용 조성물
KR102832259B1 (ko) * 2022-11-15 2025-07-09 한국한의약진흥원 지용성 활성성분의 수용해도 증진을 위한 쌍화탕의 가공방법, 이렇게 얻어진 미세 콜로이드 분산체 및 이를 포함하는 조성물
KR20240135469A (ko) 2023-03-02 2024-09-11 서원대학교산학협력단 항산화성 생약 복합추출물
KR102690568B1 (ko) * 2023-05-15 2024-07-30 조용익 한약재가 가미된 가미쌍화탕을 유효성분으로 포함하는 한방차

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100918629B1 (ko) * 2007-11-30 2009-09-25 한국 한의학 연구원 쌍화탕 유산균 발효물을 유효성분으로 함유하는 간 독성예방 또는 치료용 조성물
KR101040721B1 (ko) * 2007-11-30 2011-06-10 한국 한의학 연구원 지구자를 포함하는 가미 쌍화탕을 유효성분으로 함유하는숙취해소용 조성물
KR100988923B1 (ko) * 2009-07-17 2010-10-20 한국 한의학 연구원 쌍화탕 유산균 발효물을 포함하는 숙취해소용 조성물

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104367617A (zh) * 2014-11-06 2015-02-25 成都果睿医药科技有限公司 治疗骨质疏松的药物组合物
CN104435082A (zh) * 2014-11-06 2015-03-25 成都果睿医药科技有限公司 治疗骨质疏松的药物组合物
CN111718873A (zh) * 2020-06-19 2020-09-29 江南大学 一株具有缓解骨质疏松功效的发酵乳杆菌及其应用

Also Published As

Publication number Publication date
KR20110139473A (ko) 2011-12-29
KR101252639B1 (ko) 2013-04-09
WO2011162523A3 (fr) 2012-04-12
CN103037882B (zh) 2014-12-17
CN103037882A (zh) 2013-04-10

Similar Documents

Publication Publication Date Title
KR101252639B1 (ko) 쌍화탕 또는 이의 유산균 발효물을 포함하는 골다공증 예방 또는 치료용 조성물
KR102217525B1 (ko) 치주염 예방 또는 치료용 유산균 및 그의 용도
KR20150110378A (ko) 후발효차 추출물을 포함하는 조성물
US20250366484A1 (en) Kimchi for preventing or treating helicobacter pylori-associated diseases
KR20200008977A (ko) 약콩 발효물을 포함하는 근감소증의 예방, 치료용, 근력 개선 또는 근육량 증대용 조성물
KR101709281B1 (ko) 생약 추출물 또는 이의 유산균 발효물을 포함하는 골다공증 예방 또는 치료용 조성물
JP2003342185A (ja) リパーゼ活性阻害剤
KR101199961B1 (ko) 방풍통성산 또는 이의 유산균 발효물을 포함하는 골다공증 예방 또는 치료용 조성물
KR102420930B1 (ko) 미립화된 유산균 사균체를 포함하는 비만 예방 및 치료용 조성물
KR100874778B1 (ko) 발효청국장 추출물을 포함하는 갱년기 질환의 예방 및치료용 조성물
KR101770036B1 (ko) 오미자 추출물을 유효성분으로 포함하는 IL-1β에 의한 관절염의 예방 또는 개선용 조성물
KR100773059B1 (ko) 배당체 가수분해능을 가진 신규한 미생물, 이를 함유한 프로바이오틱스 및 이의 제조방법
KR100597235B1 (ko) 오미자 추출물을 유효성분으로 함유하는 관절염 예방 및치료용 조성물
KR101242635B1 (ko) 권백 추출물을 포함하는 골다공증 예방 또는 치료용 조성물
KR102434006B1 (ko) 항비만 활성을 갖는 유산균을 함유하는 식품 조성물
JP2012001511A (ja) 配糖体分解用組成物
KR100733335B1 (ko) 갈근 추출물의 발효물 및 이를 함유하는 골다공증 예방또는 치료용 조성물
WO2010008150A2 (fr) Composition pour prévenir ou traiter l'ostéoporose qui contient comme principe actif un mélange d'extraits de saururus chinensis et de scutellaria baicalensis
KR100555904B1 (ko) 큰느타리버섯과 오가피의 혼합 생약재 추출물 및 이를유효성분으로 하는 골다공증 예방 및 치료용 조성물
KR101683030B1 (ko) 발효 울금 추출물의 제조방법 및 이의 추출방법에 의해 얻어진 추출물을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR102217518B1 (ko) 치주염 예방 또는 치료용 유산균 및 그의 용도
KR102116046B1 (ko) 오메가3 지방산을 포함하는 인지 장애 질환 예방 또는 치료용 조성물
KR102361793B1 (ko) 블루베리 및 흑미 추출물의 발효물을 포함하는 염증성 장질환의 예방 또는 치료용 조성물
KR102014922B1 (ko) 감초 유래 글라블리딘을 유효성분으로 하는 소화기능 개선용 조성물
JP2012001510A (ja) 配糖体分解用組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180038177.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11798358

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11798358

Country of ref document: EP

Kind code of ref document: A2